Harvard Bioscience, Inc.
HBIO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $92 | $227 | $115 | $284 |
| - Cash | $4 | $4 | $5 | $8 |
| + Debt | $44 | $43 | $54 | $57 |
| Enterprise Value | $132 | $265 | $164 | $334 |
| Revenue | $94 | $112 | $113 | $119 |
| % Growth | -16.1% | -1% | -4.7% | – |
| Gross Profit | $55 | $66 | $61 | $68 |
| % Margin | 58.2% | 58.9% | 53.7% | 56.9% |
| EBITDA | -$1 | $8 | $1 | $9 |
| % Margin | -1.6% | 7.2% | 0.8% | 7.6% |
| Net Income | -$12 | -$3 | -$10 | -$0 |
| % Margin | -13.2% | -3% | -8.4% | -0.2% |
| EPS Diluted | -0.28 | -0.081 | -0.23 | -0.007 |
| % Growth | -247.8% | 65% | -3,139.4% | – |
| Operating Cash Flow | $1 | $14 | $1 | $1 |
| Capital Expenditures | -$3 | -$2 | -$2 | -$1 |
| Free Cash Flow | -$2 | $12 | -$0 | -$0 |